Although there was a suggestion of a differential association of CYP2D6 genotype according to patient ethnicity, concomitant therapy, breast cancer stage/grade and menopause status, none of the subgroup analyses surpassed our a priori Bonferroni-adjusted P-value threshold of <0.002 (Figure 3 and Figure S9). This evidence concerns the gene CYP2D6 and breast cancer.